EE200300070A - Asendatud imidasoolid kui TAFIa inhibiitorid - Google Patents
Asendatud imidasoolid kui TAFIa inhibiitoridInfo
- Publication number
- EE200300070A EE200300070A EEP200300070A EEP200300070A EE200300070A EE 200300070 A EE200300070 A EE 200300070A EE P200300070 A EEP200300070 A EE P200300070A EE P200300070 A EEP200300070 A EE P200300070A EE 200300070 A EE200300070 A EE 200300070A
- Authority
- EE
- Estonia
- Prior art keywords
- substituted imidazoles
- tafia inhibitors
- tafia
- inhibitors
- imidazoles
- Prior art date
Links
- 150000002460 imidazoles Chemical class 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Dermatology (AREA)
- Pulmonology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Rheumatology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Reproductive Health (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Pregnancy & Childbirth (AREA)
- Psychology (AREA)
- Surgery (AREA)
- Psychiatry (AREA)
- Vascular Medicine (AREA)
- Gynecology & Obstetrics (AREA)
- Pain & Pain Management (AREA)
- Ophthalmology & Optometry (AREA)
- Endocrinology (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0020346A GB0020346D0 (en) | 2000-08-17 | 2000-08-17 | Pharmaceuticals |
| GB0027409A GB0027409D0 (en) | 2000-11-09 | 2000-11-09 | Pharmaceuticals |
| GB0029556A GB0029556D0 (en) | 2000-12-04 | 2000-12-04 | Pharmaceuticals |
| PCT/IB2001/001425 WO2002014285A1 (en) | 2000-08-17 | 2001-08-08 | Substituted imidazoles as tafia inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EE200300070A true EE200300070A (et) | 2005-02-15 |
Family
ID=27255849
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EEP200300070A EE200300070A (et) | 2000-08-17 | 2001-08-08 | Asendatud imidasoolid kui TAFIa inhibiitorid |
Country Status (38)
| Country | Link |
|---|---|
| EP (1) | EP1311488B1 (cs) |
| JP (2) | JP4119746B2 (cs) |
| KR (1) | KR20030022412A (cs) |
| CN (1) | CN1443173A (cs) |
| AP (1) | AP1375A (cs) |
| AR (1) | AR035580A1 (cs) |
| AT (1) | ATE447557T1 (cs) |
| AU (1) | AU2001276605A1 (cs) |
| BG (1) | BG107330A (cs) |
| BR (1) | BR0113289A (cs) |
| CA (1) | CA2419633C (cs) |
| CY (1) | CY1109693T1 (cs) |
| CZ (1) | CZ2003388A3 (cs) |
| DE (1) | DE60140368D1 (cs) |
| DK (1) | DK1311488T3 (cs) |
| DO (1) | DOP2001000233A (cs) |
| EA (1) | EA005532B1 (cs) |
| EE (1) | EE200300070A (cs) |
| ES (1) | ES2334101T3 (cs) |
| HR (1) | HRP20030103A2 (cs) |
| HU (1) | HUP0303763A3 (cs) |
| IL (1) | IL153225A0 (cs) |
| IS (1) | IS6638A (cs) |
| MA (1) | MA26940A1 (cs) |
| MX (1) | MXPA03001425A (cs) |
| NO (1) | NO20030706L (cs) |
| NZ (1) | NZ522823A (cs) |
| OA (1) | OA12362A (cs) |
| PA (1) | PA8525401A1 (cs) |
| PE (1) | PE20020352A1 (cs) |
| PL (1) | PL361054A1 (cs) |
| PT (1) | PT1311488E (cs) |
| SI (1) | SI1311488T1 (cs) |
| SK (1) | SK1732003A3 (cs) |
| SV (1) | SV2002000602A (cs) |
| TN (1) | TNSN01126A1 (cs) |
| UY (1) | UY26889A1 (cs) |
| WO (1) | WO2002014285A1 (cs) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE0103272D0 (sv) | 2001-09-28 | 2001-09-28 | Astrazeneca Ab | Chemical compounds |
| JP2005520811A (ja) * | 2002-01-22 | 2005-07-14 | ファイザー・インク | ＴＡＦＩａインヒビターとしての３−（イミダゾリル）−２−アルコキシプロパン酸 |
| US6713496B2 (en) | 2002-01-22 | 2004-03-30 | Pfizer Inc | 3-(imidazolyl)-2-alkoxypropanoic acids |
| EP1467732A1 (en) | 2002-01-22 | 2004-10-20 | Pfizer Limited | 3-(imidazolyl)-2-aminopropanoic acids for use as tafi-a inhibitors for the treatment of thrombotic diseases |
| BRPI0409906A (pt) | 2003-04-29 | 2006-04-25 | Univ Zuerich | l-histidina protegida, metálica e orgánica derivatizada em nepsilon e/ou nalfa para acoplar ás biomoléculas para marcação altamente eficiente com [m(oh2)3(co)3]+ por coordenação de fac |
| SE0302853D0 (sv) * | 2003-10-29 | 2003-10-29 | Astrazeneca Ab | Chemical compounds |
| WO2005049027A2 (en) * | 2003-11-03 | 2005-06-02 | Probiodrug Ag | Combinations useful for the treatment of neuronal disorders |
| WO2005051384A1 (en) * | 2003-11-25 | 2005-06-09 | Pfizer Limited | Stabilised pharmaceutical compositions |
| JP2008536923A (ja) * | 2005-04-18 | 2008-09-11 | バイエル・シェーリング・ファルマ・アクチェンゲゼルシャフト | 心筋の再灌流の増強およびｐｃｉの容易化のためのｔａｆｉ阻害剤の使用 |
| DE102005049385A1 (de) | 2005-10-15 | 2007-04-19 | Sanofi-Aventis Deutschland Gmbh | Imidazolderivate als Inhibitoren von TAFIa |
| MX2009005516A (es) * | 2006-12-06 | 2009-06-04 | Sanofi Aventis | Derivados de urea y de sulfamida en calidad de inhibidores de tafia. |
| WO2009103432A2 (en) * | 2008-02-21 | 2009-08-27 | Sanofi-Aventis | Covalently binding imaging probes |
| US20110213143A1 (en) * | 2008-10-29 | 2011-09-01 | Taisho Pharmaceutical Co., Ltd. | Compound having tafia inhibitory activity |
| FR2947266B1 (fr) * | 2009-06-26 | 2011-06-17 | Servier Lab | Nouveaux derives d'acide 2-mercaptocyclopentanecarboxylique, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| US8946443B2 (en) | 2010-03-18 | 2015-02-03 | Daiichi Sankyo Company, Limited | Cyclopropanecarboxylic acid derivative |
| PT2548871T (pt) | 2010-03-18 | 2017-10-18 | Daiichi Sankyo Co Ltd | Derivado de imidazol substiuído com cicloalquilo |
| CN103534293B (zh) * | 2011-05-17 | 2015-10-21 | 法玛西泰股份公司 | 用于粘连治疗和预防的化合物、化合物相关的药物组合物及用于预防和治疗粘连的方法 |
| HUE037591T2 (hu) * | 2011-07-22 | 2018-09-28 | Cambrex Karlskoga Ab | Új eljárások 4. szénatomon szubsztituált imidazolok elõállítására |
| WO2013039202A1 (ja) * | 2011-09-15 | 2013-03-21 | 第一三共株式会社 | 新規アクリル酸誘導体 |
| CA2914533A1 (en) | 2013-06-10 | 2014-12-18 | Sanofi | Macrocyclic urea derivatives as inhibitors of tafia, their preparation and their use as pharmaceuticals |
| DK3359528T3 (en) | 2015-10-07 | 2022-03-07 | Mitobridge Inc | Ppar agonists, compounds, pharmaceutical compositions, and methods of use thereof |
| FR3046793B1 (fr) * | 2016-01-14 | 2018-01-05 | Les Laboratoires Servier | Nouveaux derives de phosphinanes et azaphosphinanes, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| JPWO2017170460A1 (ja) * | 2016-03-29 | 2019-02-07 | 第一三共株式会社 | 炎症性腸疾患治療剤 |
| EP3442948B1 (en) | 2016-04-13 | 2020-12-16 | Mitobridge, Inc. | Ppar agonists, compounds, pharmaceutical compositions, and methods of use thereof |
| CN113943255B (zh) * | 2020-07-17 | 2024-08-06 | 深圳信立泰药业股份有限公司 | 一种手性3-(4-环丙基-2,5-二氧杂咪唑啉-4-基)丙酸的制备方法 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS6163661A (ja) * | 1984-09-05 | 1986-04-01 | Microbial Chem Res Found | ヒスタジン関連化合物 |
| US5993815A (en) * | 1996-11-08 | 1999-11-30 | University Of Vermont | Methods and compositions for inhibiting the activation of thrombin-activatable fibrinolysis inhibitor (TAFI) |
| SE9901572D0 (sv) * | 1999-05-03 | 1999-05-03 | Astra Ab | New compounds |
-
2001
- 2001-08-08 CZ CZ2003388A patent/CZ2003388A3/cs unknown
- 2001-08-08 DE DE60140368T patent/DE60140368D1/de not_active Expired - Lifetime
- 2001-08-08 PT PT01954264T patent/PT1311488E/pt unknown
- 2001-08-08 SI SI200130950T patent/SI1311488T1/sl unknown
- 2001-08-08 DK DK01954264T patent/DK1311488T3/da active
- 2001-08-08 HU HU0303763A patent/HUP0303763A3/hu unknown
- 2001-08-08 NZ NZ522823A patent/NZ522823A/en unknown
- 2001-08-08 AT AT01954264T patent/ATE447557T1/de active
- 2001-08-08 CA CA2419633A patent/CA2419633C/en not_active Expired - Fee Related
- 2001-08-08 CN CN01813131A patent/CN1443173A/zh active Pending
- 2001-08-08 WO PCT/IB2001/001425 patent/WO2002014285A1/en not_active Application Discontinuation
- 2001-08-08 EE EEP200300070A patent/EE200300070A/xx unknown
- 2001-08-08 EP EP01954264A patent/EP1311488B1/en not_active Expired - Lifetime
- 2001-08-08 JP JP2002519428A patent/JP4119746B2/ja not_active Expired - Fee Related
- 2001-08-08 KR KR10-2003-7002279A patent/KR20030022412A/ko not_active Ceased
- 2001-08-08 BR BR0113289-0A patent/BR0113289A/pt not_active Application Discontinuation
- 2001-08-08 EA EA200201239A patent/EA005532B1/ru not_active IP Right Cessation
- 2001-08-08 OA OA1200300039A patent/OA12362A/fr unknown
- 2001-08-08 PL PL36105401A patent/PL361054A1/xx not_active Application Discontinuation
- 2001-08-08 HR HR20030103A patent/HRP20030103A2/hr not_active Application Discontinuation
- 2001-08-08 ES ES01954264T patent/ES2334101T3/es not_active Expired - Lifetime
- 2001-08-08 AU AU2001276605A patent/AU2001276605A1/en not_active Abandoned
- 2001-08-08 IL IL15322501A patent/IL153225A0/xx unknown
- 2001-08-08 SK SK173-2003A patent/SK1732003A3/sk unknown
- 2001-08-08 MX MXPA03001425A patent/MXPA03001425A/es active IP Right Grant
- 2001-08-14 PA PA20018525401A patent/PA8525401A1/es unknown
- 2001-08-15 PE PE2001000815A patent/PE20020352A1/es not_active Application Discontinuation
- 2001-08-15 UY UY26889A patent/UY26889A1/es not_active Application Discontinuation
- 2001-08-15 AR ARP010103900A patent/AR035580A1/es unknown
- 2001-08-16 TN TNTNSN01126A patent/TNSN01126A1/fr unknown
- 2001-08-16 SV SV2001000602A patent/SV2002000602A/es unknown
- 2001-08-16 AP APAP/P/2001/002250A patent/AP1375A/en active
- 2001-11-14 DO DO2001000233A patent/DOP2001000233A/es unknown
-
2002
- 2002-11-28 IS IS6638A patent/IS6638A/is unknown
- 2002-11-28 BG BG107330A patent/BG107330A/xx unknown
-
2003
- 2003-02-04 MA MA27025A patent/MA26940A1/fr unknown
- 2003-02-14 NO NO20030706A patent/NO20030706L/no not_active Application Discontinuation
-
2008
- 2008-02-27 JP JP2008045382A patent/JP4778531B2/ja not_active Expired - Fee Related
-
2009
- 2009-12-30 CY CY20091101349T patent/CY1109693T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EE200300070A (et) | Asendatud imidasoolid kui TAFIa inhibiitorid | |
| EE200200140A (et) | Pteridinoonid kui kinaasi inhibiitorid | |
| DE60211317D1 (de) | Rho-kinase inhibitoren | |
| DE60218138D1 (de) | Rho-kinase inhibitoren | |
| DE60320933D1 (de) | Rho-kinase inhibitoren | |
| NO20030472D0 (no) | Imidazolderivater | |
| DE60128709D1 (de) | Triazol-verbindungen als protein-kinase-inhibitoren | |
| EE200100368A (et) | w-karboksüarüülasendatud difenüülkarbamiidid kui raf-kinaasi inhibiitorid | |
| ATE524441T1 (de) | Vla-4-inhibitoren | |
| IS7138A (is) | Alkýn-arýl fosfódíesterasa-4 hindrar | |
| ATE505471T1 (de) | Azaindol-kinaseinhibitoren | |
| ATE437862T1 (de) | Pyrimidin-5-onderivate als ldl-pla2 inhibitoren | |
| ATE360620T1 (de) | Imidazolderivate | |
| DE60203995D1 (de) | Triazoloverbindungen als mmp-inhibitoren | |
| IS7599A (is) | Heterósýklískir kínasatálmar | |
| DK1272488T3 (da) | Tri-aryl-substitueret ethan-PDE4-inhibitorer | |
| NO20023013D0 (no) | Substituerte 8-arylkinolinfosfodiesterase-4-inhibitorer | |
| EE200300266A (et) | Asendatud 8-arüülkinoliinid kui fosfodiesteraas-4inhibiitorid | |
| NO20014875D0 (no) | Promedikamenter for trombin inhibitorer | |
| NO20025659L (no) | Heterocykliske forbindelser | |
| PT1217002E (pt) | 2-(4-piridinil)-benzofuranos como inibidores de metaloproteases | |
| DE60009260D1 (de) | Thiopyranderivate as mmp-inhibitoren | |
| NO20023298L (no) | Nye imidazolderivater | |
| AR028075A1 (es) | Inhibidores de la peptido-desformilasa | |
| DK1296985T3 (da) | Heteropolycykliske inhibitorer |